HC Wainwright Reiterates Buy Rating for GALT with $11 Target
HC Wainwright maintains its buy rating for GALT, setting a price target of $11, a 165.69% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating for GALT on June 23, 2026, with a price target of $11.
- HC Wainwright's $11 price target implies 165.69% upside from Galectin Therapeutics Inc.'s ($GALT) current $4.14 share price.
- GALT shares traded at $3.50 on Tuesday, reflecting ongoing interest from institutional investors.
- Vanguard Capital Management opened a new position in GALT, while Marshall Wace increased its stake by 102.6%.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 23, 2026, HC Wainwright reiterated its buy rating for GALT, setting a price target of $11. The analyst Matthew Keller maintains a positive outlook on the stock, which traded at $3.50 on Tuesday.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in GALT
Vanguard Capital Management opened a new position in GALT, acquiring 1,966,542 shares valued at approximately $5.49 million. Marshall Wace increased its holdings by 617,778 shares, a 102.6% rise, bringing its total to 1,219,912 shares worth about $3.40 million. Osaic Holdings also boosted its stake by 32,080 shares, a 2.9% increase, ending with 1,122,670 shares valued at $3.13 million. BlackRock added 2,679 shares, a modest 0.3% increase, to hold a total of 799,237 shares valued at $2.23 million. Meanwhile, Millennium Management significantly expanded its position by 562,926 shares, a 239% jump, resulting in 798,434 shares worth $2.23 million.
Insider Buying and Selling at Galectin Therapeutics Inc.
On May 26, 2026, Jamil Khurram, Chief Medical Officer, executed both a sale and a purchase of 568 shares at $3.10 and $1.23 per share, respectively. Additionally, Brem Henry acquired 60,000 shares on March 12, 2026, while Eldred Kary bought 300 shares at $2.70 each on February 6, 2026.
Analysts Set New Price Targets
On June 23, 2026, HC Wainwright & Co. reiterated its buy rating on GALT with a price target of $11. This follows a December 17, 2025, rating where the firm maintained its buy stance with the same target. The consensus among analysts remains positive, with a buy recommendation and an average target price reflecting confidence in the stock's potential.
Bottom Line
HC Wainwright's reiterated buy rating and $11 target for GALT suggest continued optimism in the company's prospects. Institutional investors like Vanguard Capital Management and Millennium Management have shown interest, reflected in their recent stake increases. As always, remember that 13F filings and analyst ratings are backward-looking and may not represent current positions or outlooks.
Get Galectin Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $GALT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.